While the term epigenetics is often used loosely, and sometimes in rather diff erent ways, the term is generally considered to encompass changes in DNA methylation, histone modifi cations, miRNA expression, and nucleosome positioning and higher order chromatin as epi genetic changes aff ecting gene regulation. Epigenetics was defi ned as a discipline more than 50 years ago, by CH Waddington, and originally described changes in the development of organisms that could not be explained by changes in DNA. Subsequently it became clear that epigenetic modifi cations play important roles in diseases, including breast cancer. Th ere is thus a pressing need to understand the functional genome; that is, the changes defi ned by regulatory mechanisms overlaying the genetic structure.
Introduction
While the term epigenetics is often used loosely, and sometimes in rather diff erent ways, the term is generally considered to encompass changes in DNA methylation, histone modifi cations, miRNA expression, and nucleosome positioning and higher order chromatin as epi genetic changes aff ecting gene regulation. Epigenetics was defi ned as a discipline more than 50 years ago, by CH Waddington, and originally described changes in the development of organisms that could not be explained by changes in DNA. Subsequently it became clear that epigenetic modifi cations play important roles in diseases, including breast cancer. Th ere is thus a pressing need to understand the functional genome; that is, the changes defi ned by regulatory mechanisms overlaying the genetic structure.
Over the past few years there has been an explosion in studies of epigenetics in breast cancer, refl ected by the exponential increase of published manuscripts (Figure 1) . A PubMed search for the keywords 'epigenetic' and 'breast cancer' reveals that the fi rst publication was in 1983. Progress was slow until approximately 10 years ago when the number of studies started to steadily increase, at least in part fueled by improved technologies. In the present review, we focus on recent advances in the understanding of histone methylation and demethylation, a relatively new area with promise for clinical translation. We also review recent studies that have utilized genomewide technologies for the study of DNA methylation. Much progress has been made in the characterization of noncoding RNAs, and the eff ect of higher order chromatin structure on gene expression in breast cancer; however, these discoveries lie outside the scope of our review.
Finally, we also discuss the relatively slow translation of results from the epigenetic fi eld into the clinic. Although there has been a dramatic increase of research into the epigenetics of breast cancer and milestone discoveries have undoubtedly been made, the application of such fi ndings into the clinical setting has been slow. Th is is in contrast to other areas -for example, profi ling of gene expression, where we have witnessed a revolution in the past 4 to 6 years, especially in the translation of the results into the development of US Food and Drug Administration-approved multigene prognostic assays. Why have we not yet seen any predictive/prognostic tests that involve the characterization of epigenetic changes? In a similar way, although a number of drugs targeting epigenetic changes have been tested, at this time no epigenetic drug has received US Food and Drug Administration approval in breast cancer treatment. Is this a result from a slower development of techniques used for epigenetic analysis? Or are there additional Abstract Epigenetic changes are critical for development and progression of cancers, including breast cancer. Signifi cant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modifi cation, miRNA expression, and higher order chromatin structure aff ect gene expression. The present review will focus on methylation and demethylation of histones. While the acetylation of histones has been at the forefront of well-characterized post-translational modifi cations of histones, including the development of inhibitors targeting de-acetylating enzymes, the past few years have witnessed a dramatic increase in knowledge regarding the role of histone methylation/ demethylation. This is an exciting and rapidly evolving area of research, with much promise for potential clinical intervention in several cancers including breast cancer. We also summarize eff orts to identity DNA methylation signatures that could be prognostic and/ or predictive markers in breast cancer, focusing on recent studies using genome-wide approaches. Finally, we briefl y review the eff orts made by both the National Institutes of Health Epigenome Project and The Cancer Genome Atlas, especially highlighting the study of breast cancer epigenetics, exciting technological advances, potential roadblocks, and future directions.
obstacles? In the present review article we discuss some barriers to more rapid translation of epigenetic studies in breast tumors into clinical practice, and discuss the eff orts by the Epigenome Project and Th e Cancer Genome Atlas (TCGA) that are expected to bring dramatic progress in the near future.
Acetylation and methylation of histones in breast cancer
For many years it has been known that post-translational modifi cations of histone tails determine, in part, which regions of the genome are in an open and thus trans criptionally active conformation, and which are closed and thus transcriptionally inactive. Th e modifi cations of histone tails include acetylation, methylation, ubiquitylation, phosphorylation, sumoylation, and ribosylation, each of which can signifi cantly aff ect the expression of genes [1] . Th e most studied histone modifi cations are histone acetyla tion/deacetylation, and more recently methyla tion/ demethylation. In breast cancer, abnormal histone modifi cation in combination with DNA hypermethylation is frequently associated with epigenetic silencing of tumor suppressor genes and genomic instability [2, 3] . Understanding the mechanisms of dysregulation of histone tail post-translational modifi cations and their contribution to breast tumorigenesis is critically important in the development of novel targeted therapy for breast cancer patients.
Inhibition of histone deacetylases as a therapeutic approach in breast cancer
Th e dynamic nature of histone acetylation is determined by the counterbalancing activity of histone acetyl transferases and histone deacetylases (HDACs). Th e HDAC family is divided into zinc-dependent enzymes (classes I, IIa, IIb, and IV, of which there are 11 subtype enzymes) and zinc-independent enzymes (class III, also called sirtuins), which require NAD + for their catalytic activity [4] . Over the past decade, a number of HDAC inhibitors have been rationally designed and synthesized based on their chemical structures and divided into four groups: hydroxamic acids, cyclic tetrapeptides, short-chain fatty acids, and benzamides [5] . Most of the HDAC inhibitors developed so far are nonselective, and among the most potent inhibitors are those that have been designed to target primarily the zinc cofactor at the active site of the HDACs and to exhibit their eff ects in the nanomolar or micromolar range [6, 7] . Some of these HDAC inhibitors were shown to change the chromatin structure and cause re-expression of aberrantly silenced genes, which in turn is associated with growth inhibition and apoptosis in cancer cells [8, 9] . In estrogen receptor (ER)-negative breast cancer cells, inhibition of HDAC activity by specifi c HDAC inhibitors reactivates ERα and progesterone receptor (PR) gene expression, which are known to be aberrantly silenced [10] [11] [12] [13] [14] . Pruitt and colleagues demonstrated that inhibition of class III HDAC SIRT1 using a pharmacologic inhibitor, splitomicin, or siRNA reactivates epigenetically silenced SFRP1, SFRP2, Ecadherin, and CRBP1 genes in human breast cancer cells [15] .
Th e study of HDAC inhibitors is moving rapidly into a new stage of development that has now started to produce encouraging results in the clinic, particularly in the fi eld of cancer therapy. Vorinostat (SAHA) and romidepsin (FK228) have already been approved by the US Food and Drug Administration for the clinical treatment of cutaneous T-cell lymphoma. Vorinostat is currently under evaluation in several phase II trials in breast cancer [16, 17] , including combination therapy of vorinostat with standard cytotoxic agents (for example, paclitaxel), endocrine therapy (tamoxifen), or novel targeted therapy (trastuzumab, bevacizumab) [3, 16, 17] . Other HDAC inhibitors such as MS-275 (entinostat) and LBH-589 (panobinostat) are in phase I/II studies in combination with other agents, such as trastuzumab, in women with metastatic HER2-positive breast cancer [16] .
In addition, increasing evidence suggests that combination treatment with inhibitors of HDAC and DNA methyltransferase (DNMT) results in synergy at clinically tolerable doses that may translate not only into changes in methylation but also to disease response. Preclinical studies of HDAC inhibitors in combination with DNMT inhibitors have shown superior re-expression of silenced genes and increased apoptosis in colon/lung cancer cell lines [18] , reduced tumorigenesis in lung cancer models [19, 20] , superior ER re-expression compared with HDAC inhibitor alone in breast cancer cell lines [12] , and res tora tion bers of "epig cancer" Pub of tamoxifen responsiveness [13, 21] . In a phase I clinical trial of phenylbutyrate in combination with the DNMT inhibitor 5-azacitidine in myelodysplasia, res ponse was highly correlated with reversal of aberrantly methylated genes [22] . In another phase I trial in non small-cell lung cancer, the combination of a DNMT inhibitor and an HDAC inhibitor was safe and tolerable, and was associated with clinical activity [23] . An ongoing phase II trial is testing the HDAC inhibitor entinostat (also known as SNDX-275 and MS-275), in combination with 5-azacitidine, in patients with hormonerefractory or triple-negative metastatic breast cancer. Th e primary endpoint will be the objective response rate; secondary endpoints will be progression-free survival, overall survival, and clinical benefi t rate, as well as safety and tolerability. Other analyses will include the pharmaco kinetics of 5-azacitidine and entinostat, cytidine deaminase activity, pharmacogenetics, and baseline and change in gene methylation in circulating DNA prior to/ following combination therapy (quantitative multiplex methylation specifi c PCR). Th e study will also aim to evaluate baseline and change in malignant tissue via mandatory biopsies prior to/following combination therapy of gene methylation of candidate genes (by quantitative methylation specifi c PCR) and of genomewide methylome, coupled with the study of candidate gene re-expression (RT-PCR). We are at a critical turning point, because results from these critical studies will guide future trials with HDAC inhibitors.
Targeting histone lysine methylation and demethylation in breast cancer
Histone lysine methylation is a reversible process, dynami cally regulated by both lysine methyltransferases and demethylases ( Figure 2 ). In general, methylation of histone H3 lysine 4 (H3K4me), H3K36, or H3K79 is associated with active transcription, whereas methylation of H3K9, H3K27, or H4K20 is associated with gene silenc ing [1] . Histone methylation is regulated in breast cancer in an even more complicated manner than histone acetylation via a large number of chromosomal remodeling regulatory complexes.
Modifi cation of H3K4 methylation is catalyzed by the Trithorax group of histone methyltransferases, including SET1 and MLL [24] . Th e activity of Trithorax proteins is balanced by the opposing eff ects of the Polycomb group factors, another important histone methyltransferase family that mediates methylation usually associated with epigenetic gene silencing [25] . Polycomb group proteins form at least four diff erent complexes, including the maintenance complex PRC1 -composed of RING, HPC, HPH, and BMI1 -and three diff erent initiation complexes, PRC2 through PRC4, which are formed by core component of zeste homolog 2 (EZH2), suppressor of zeste 12 (SUZ12), and Nurf-55 [26, 27] . EZH2 is a highly conserved histone methyltransferase that specifically targets H3K27 and functions as transcriptional repressor [28] . Tissue microarray analysis of breast cancers identifi ed consistent overexpression of EZH2, which was strongly associated with tumor aggressiveness [29] . Studies from several groups demonstrated that expres sion of EZH2 is signifi cantly associated with increased proliferation and other features of aggressive breast cancer, such as p53 altera tions, c-erbB-2 expres sion, markers of the basal-like subtype, and glomeruloid microvascular proliferation [30, 31] . Finally, in a recent report by Chang and colleagues, EZH2 was shown to repress DNA repair in breast-tumor-initiating cells, potentially leading to expansion of stem-cell-like cells, and fi nally to breast cancer progression [32] . Collectively, these results suggest that EZH2 might function as a prognostic biomarker in breast cancer, and might also be a promising treatment target.
Histone lysine-specifi c demethylase 1 (LSD1, also known as BHC110, AOF2, or KDM1) is the fi rst identifi ed histone lysine demethylase capable of specifi cally demethy lating monoethylated and dimethylated lysine 4 of histone H3 (H3K4me1 and H3K4me2) [33, 34] . Th e discovery of LSD1 has revolutionized the concept of histone methylation as a dynamically regulated process under enzymatic control, rather than chromatin marks that could only be changed by histone replacement. Th e activity of the LSD1-CoREST-HDAC complex has been implicated in tumori genesis. A recent study using ELISA determined that LSD1 is highly expressed in ER-negative breast tumors, and hence LSD1 was suggested to serve as a predictive marker for aggressive breast tumor biology and a novel attractive therapeutic target for treatment of ER-negative breast cancers [35] . In ER-positive human breast cancer MCF-7 cells, 42% and 58% of all Pol II and ERα-bound promoters, respectively, were found to be bound by LSD1, and the recruitment of LSD1 to the promoters of LSD1 + /ERα + target genes was stimulated by estradiol [36] .
Intriguingly, Perillo and colleagues reported that LSD1-mediated demethylation produces H 2 O 2 , which subsequently modifi es the surrounding DNA and recruits 8-oxoguanine-DNA glycosylase 1 and topoisomerase IIβ, triggering conformational changes in DNA and chromatin that are essential for estrogen-induced transcription [37] . Our recent study demonstrated that LSD1 interacts closely with HDACs in human breast cancer cells. Importantly, inhibitors of histone demethylation and deacety lation exhibit cooperation and synergy in regulating gene expression and growth inhibition, and may represent a promising and novel approach for epigenetic therapy of breast cancer [38] . Recent studies also revealed that LSD1 is able to demethylate nonhistone substrates such as p53 and DNMT1, indicating broader biological functions for LSD1 [39, 40] .
Subsequent to the discovery of LSD1, other Jumonji C (JmjC) domain-containing proteins were proposed to function as human histone demethylases. Th ese enzymes use α-ketoglutarate and iron as cofactors to demethylate histone lysine residues through a hydroxylation reaction [41] [42] [43] [44] . Little is known about the role of JmjC domaincontaining histone demethylase in breast cancer, but recent studies found that PLU-1 (also known as JARID1B or KDM5B) contributes to MCF-7 cell proliferation by facilitating G 1 progression. Further, knockdown of PLU-1 led to a signifi cant reduction of MCF-7 cell proliferation and upregulation of expression of certain tumor suppressor genes, including 14-3-3σ, BRCA1, CAV1, and HOXA5 [45] . Sharma and colleagues reported that the development of drug-tolerant cancer cells was at least in part mediated by activities of the histone demethylase JARID1A/KDM5A. While these studies focused on epidermal growth factor receptor-targeting small-molecule inhibitors in lung cancer cells, the authors showed that a similar mechanism for resistance existed for other therapies, such as cis-platin. One could thus rationalize that activation of this pathway might be a more widespread phenomenon for the development of drug resistance in JARID1A/KDM5A-expressing tumors [46, 47] .
Emerging therapeutic potential of histone methyltransferase and demethylase inhibitors in breast cancer
As depicted in Figure 2 , histone methylation is the result of a dynamic equilibrium between activities of a number of histone methyltransferases and demethylases. Given the increasing evidence for their role in tumorigenesis, it is no surprise they are being developed and tested as novel treatment targets.
Enhanced activity of histone-modifying enzymes such as LSD1 and EZH2 leads to epigenetic silencing of critical genes, such as tumor suppressor genes, that have been shown to play an important role in breast tumor tumorigenesis. A series of novel compounds function as powerful inhibitors of histone methylation or demethy lation and are capable of inducing re-expression of aberrantly silenced genes important in breast tumorigenesis. A list of identifi ed histone methyltransferase and demethylase inhibitors is presented in Table 1 . One of the fi rst histone methyltransferase inhibitors developed is chaetocin, which exhibits some selectivity for the SUV39 class of histone methyltransferases [48] . Th e EZH2 inhibitor DZNep induces robust apoptosis in breast cancer cells, at least in part by including a novel apoptosis eff ector, FBXO32 [49] . SMYD3 is a H3K4-specifi c methyltransferase that is frequently overexpressed in a variety of cancers, includ ing breast cancer [50] . Novobiocin, known as a HSP90 inhibitor, decreases the expression of SMYD3 and inhibits the proliferation and migration of MDA-MB-231 cells in a dose-dependent fashion [51] . Th e structural and catalytic similarities of LSD1 and monoamine oxidase or polyamine oxidase provided the rationale to investigate whether existing monoamine oxidases or polyamine oxidase inhibitors might also act as inhibitors of LSD1. Subsequently, the monoamine oxidase inhibitors tranylcypromine, clorgyline, and pargyline were shown to inhibit LSD1 activity and inhibit growth of breast cancer and prostate cancer cells [35, 52, 53] . Interestingly, pargyline (Eutonyl; SigmaAldrich, St Louis, MO, USA) has already been clinically used for the treatment of vascular hypertension, and tranylcypromine (Parnate; Sigma-Aldrich, St Louis, MO, USA) is a drug used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders. Unless there are toxicities due to the high doses that might be required to inhibit LSD1, one might expect this drug to be tested in the cancer arena soon.
More recently, polyamine-based LSD1 inhibitors were identifi ed and demonstrated to reactivate epigeneticsilenced tumor suppressor genes in cancer cells [54, 55] . Treatment with the LSD1-inhibiting polyamine analogues 2d or PG-11144 signifi cantly enhanced global H3K4me2 and altered gene expression in breast cancer MDA-MB-231 cells [56] . Treatment with the LSD1 inhibitor PG-11144 and the DNMT inhibitor 5-aza-2-deoxycytidine resulted in signifi cant inhibition of the growth of established tumors in a xenograft model of human colon cancer in nude mice [55] . N-oxalylglycine, an analog of α-keto glutarate, has been shown to be an inhibitor of the JmjC domain-containing histone demethylases JMJD2A and JMJD2C [57] . Th ese advances show the promise of using novel compounds that target the histone methylation/demethylation pathway as an innovative approach to breast cancer treatment, and are anticipated to lead to the development of a new generation of therapeutically eff ective epigenetically-active drugs with considerable clinical potential.
The DNA epigenome in breast cancer

Single-marker studies in breast cancer
Over the past decade, signifi cant progress has been made in the identifi cation and characterization of altered DNA methylation in breast cancer development and progression. A number of genes have been consistently reported to be methylated, including RASSF1A, ERα, PR, RARβ, CCND2, and PITX2. We will not review these fi ndings here, but would like to point the interested reader towards a number of comprehensive reviews on this topic [20, 58, 59] . Th e other frequently hyper methylated gene with a tumor-specifi c methylation profi le is BRCA1 [60, 61] . Although it has become clear that inactivation of BRCA1 by epigenetic means is a critical event in breast (and ovarian) tumorigenesis, diff er ences in experimental approaches and also in the region of the BRCA1 promoter analyzed resulted in ranges of methylation, and thus warrant some further analysis. In any case, in the present review we will focus on results from some recent genome-wide methylation studies in breast cancer.
Analysis of the breast cancer epigenome using genomewide approaches
Unprecedented advances have been made in the development of techniques to study genome-wide DNA methy lation. Briefl y, there are currently four major approaches to identify 5-methylcytosine: restriction endonucleasebased analysis, bisulfi te-conversion of DNA, affi nity and immunoprecipitation-based studies (methyl Cp6 binding domain (MBD) pulldown, or antibodies against 5-methylcytosine in DNA or against proteins binding to 5-methylcytosine, such as MBD2 and MeCP2), and fi nally mass spectrometry-based analysis. Most of the approaches have been adapted to be used for genomewide studies using array-based or sequencing-based methods, and some have been utilized to study methylation of the breast cancer genome, as discussed below.
In 2007 Ordway and colleagues used cytosine methylation-dependent restriction enzyme McrBC coupled with array hybridization to analyze methylation in nine matched invasive ductal carcinoma and adjacent normal tissue [62] . Th ey identifi ed 220 diff erentially methylated loci, and analyzed 16 genes that were able to diff erentiate breast tumor from normal and benign tissues and blood in more detail. One of these genes was GHSR, a member of the G-protein-coupled receptor that binds to ghrelin. Methylation of GHSR was able to diff erentiate invasive ductal carcinoma from normal or benign breast tissue with high specifi city and sensitivity. Th e same group went on to study four of the highly methylated loci -GHSR, max gene-associated, nuclear factor I/X, and an unannotated region on chromosome 7 -in more detail through bisulfi te pyrosequencing using DNA from breast tumors, normal breast, and sera from cancer patients and from normal controls. Disappointingly, no tumor-specifi c methylation pattern could be identifi ed, and high methy la tion rates were detected in normal sera [63] . Th e latter would clearly pose a problem for the development of sera-based assays and highlights the need to identify markers that are not methylated in normal serum. Ruike and colleagues reported results from a genomewide methylated DNA immunoprecipitation-sequencing study in breast cancer cells [64] . Briefl y, they identifi ed methylated DNA in eight breast cancer cell lines and one normal breast cell line, and in addition they compared methylation rates between parental MCF-7 cells and MCF-7 cells that had undergone epithelial to mesenchymal transition. As expected, the cancer cell lines were characterized by global hypomethylation, concurrent with hypermethyla tion of many loci. Th e hypomethylation, which was distributed throughout the entire genome, was three to fi ve times more frequent than hypermethylation, which was clustered at specifi c loci. Intriguingly, 53% of methylated CpG was found outside CpG islands. Of interest was also the association of epithelial to mesenchymal transition with hypomethylation at many CpG islands, a fi nding that deserves follow-up.
It will be of great value to apply these approaches to answer clinical questions, such as the association of genome-wide changes in DNA methylation with diff erent grades or stages of breast tumor. A recent genome-wide study by Fang and colleagues [65] has suggested that a CpG island methylator phenotype (CIMP) exists in breast cancer. Th is breast cancer CIMP provided a distinct epigenomic profi le, which was associated with genes that make up the metastasis transcriptome. Additional studies need to be performed before one can confi dently state that there are CIMP tumors associated with specifi c tumor phenotypes. Another interesting question is the association between methylation and molecular subtypes of breast tumors.
A recent study by Holm and colleagues suggests that luminal tumors have higher frequencies of methylation compared with basal or triple-negative breast tumors [58] . Briefl y, the authors studied 189 frozen primary breast tumors using the Illumina Golden Gate Methylation Cancer Panel, covering 1,505 CpG loci in 807 cancer-related genes. Unsupervised clustering revealed that methylation patterns were associated with luminal A, luminal B, and basal-like tumors, with luminal B tumors being most methylated and basal-like tumors being the least methylated. As previously reported, Her-2 tumors are very heterogeneous and are mainly driven by amplifi cation of Her-2 as the common denominator. High expression of PRC2 and low methylation of known PRC2 targets in basal-like tumors suggest that PRC2 targets might be silenced by trimethylation of H3K27 in this tumor subset. In general, these data clearly suggest that methylation plays a signifi cant role in the diff erent breast tumor subsets, and it will be critical to determine the mechanism that drives diff erent methylation states. Th e authors speculate a role for genetic changes in methylation enzymes, an interesting hypothesis that is testable.
Lineage-specifi c methylation was also observed in a methylation study performed by Sproul and colleagues [66] , who used 27K Infi nium arrays to study the methylation at >14,000 genes in 19 breast cancer cell lines and 47 primary tumors. Th e authors bring forward the argument that DNA methylation in breast tumors is a marker of cell lineage rather than tumor progression. Th is study again emphasizes the need to identify tumor-specifi c methylation events, a task most critical for the future use of DNA methylation for diagnosis and treatment of breast cancer.
Another clinical question is the involvement of DNA methylation in the adaptation of cancer cells to treatment exposure. We recently performed an MBD-pulldown assay in breast cancer cells deprived of estrogen, thus mimicking treatment with aromatase inhibitors. Th is approach resulted in the identifi cation of a large number of hypermethylated genes, and fewer that were hypomethylated (Pathiraja and colleagues, manuscript in preparation). It will be of great interest to expand those studies to clinical samples, in order to identify markers of resistance, and potential drug targets.
Clearly, these studies are only the beginning for the use of genome-wide methylation studies. With the advent of improved technologies, we should expect to witness an explosion of studies aimed at understanding epigenetic changes in breast cancer. Th is not only refers to DNA methylation, but also to other epigenetic changes, such as histone modifi cation, which can now also be studied genome wide through the use of chromatin immunoprecipitation technologies At least in part, these eff orts should soon benefi t from the results of the Human Epigenome Project and TCGA, as briefl y discussed below.
Epigenome Project and TCGA: their role in understanding epigenetics of breast cancer (and other diseases)
Description of Epigenome Roadmap initiatives
Th e Epigenome Project is a Roadmap initiative led by several National Institutes of Health (NIH) centers, started in 2008 when the NIH decided to invest over $190 million to accelerate the advancement of biomedical research in epigenomics. A series of fi ve initiatives was therefore created. Th e fi rst initiative is the creation of reference epigenome mapping centers, which support the development of reference epigenomes of a variety of human cells, including normal breast epithelial cells. Th e data gathered include information on DNA methylation, histone modifi cations, and associated noncoding RNAs. Th e second initiative focuses not only on coordinating the banking of data, but also on facilitating its access to the public, accomplished through the creation of the Epigenomic Data Analysis and Co ordination center. Th e third initiative seeks to advance technology in epigenetic research, by enabling the development of new techniques, including the creation of methods that allow in vivo imaging of epigenetic changes. Th e objective of the fourth initiative is to identify epigenetic marks and establish their function in mammalian cells. Finally, the intention of the fi fth initiative is to identify those epigenetic changes that are the cause of specifi c diseases, including breast cancer.
Importantly, the NIH roadmap initiative is part of an international association, the International Human Epigenome Consortium, which has made several recommendations with regard to data release, format, and various technical considerations, in order to universalize and validate fi ndings [67] . Regarding the former, it is recommended that all data be made available through one of several public databases, such as GEO, ARRAYEXPRESS, and DDBJ.
Funded roadmap initiatives have resulted in many fundamental contributions, including a study published late in 2009 that presented the fi rst genome-wide, singlebase resolution map of methylated cytosines in the mammalian genome from both human embryonic stem cells and fetal fi broblasts [68] . Importantly, almost onequarter of all methylation identifi ed in stem cells was in a non-CpG context, a fi nding that does not seem to be restricted to methylation in stem cells. Subsequently, an approach was developed to sequence chromatin-immunoprecipitated DNA from limited cell populations, an approach most critical for working with clinical samples [69] . A study by Ernst and Kellis described a multivariate Hidden Markov Model to reveal chromatin states in human T cells through the systematic analysis of 51 chromatin states, including promoter-associated states, transcription-associated states, active intergenic states, large-scale repressed states, and repeat-associated states [70] .
Finally, two studies have explored the strengths and weaknesses of four methods of DNA methylation mapping technologies, while providing recommendations on the design of case-control studies in epigenomics [71, 72] . Th ese studies mark a critical milestone for the Human Epigenome Project, since the development of genome-wide tech nology has been a major focus on the initiative. Briefl y, six methods were tested, of which fi ve were sequence-based and one was array-based. Each method was subjected to rigorous testing, and to statistical analysis of at least two replicate samples. Although resolution and coverage diff ered, there was high concordance between the diff erent methods, providing a high level of con fi dence for all epigenetic researchers, and providing fl exibility as to which methods to choose based on the need for resolution, the amount of available starting material, and, last but not least, the budget.
NIH Roadmap studies deciphering the breast cancer epigenome
Th e initiative also funded disease-specifi c studies, including those in breast cancer. One such study is the analysis of special AT-rich sequence binding 1 (SATB1) in metastatic breast cancer. Th e Kohwi-Shigematsu laboratory identifi ed SATB1, originally described as a genome organizer in thymocytes [73] [74] [75] , to be a key deter minant in breast cancer metastasis [76] .
While there is some controversy about the detailed function of SATB1 in breast cancer [77] , there is no doubt that SATB1 functions as a critical, global, genome organizer by recognizing and binding to specialized DNA sequences in the genome that have a high propensity to unwind (base-unpairing regions). SATB1 organizes chromatin into loops through binding of base-unpairing regions, which are found in gene-rich regions, and can regu late a large number of distally located genes by functioning as a landing platform for multiple chromatin remodeling/modifying proteins that confer specifi c epigenetic marks [78] . In breast cancer, once SATB1 becomes expressed, it regulates ~1,000 genes, including those involved in cancer progression, metastasis, and growth (for example, ERBB2, transforming growth factor beta).
Th e Kohwi-Shigematsu group is currently using genome-wide approaches to map all base-unpairing regions in the genome and to determine which particular subset of these is bound by SATB1, and whether these specifi c epigenomic modifi cations are associated with poor-prognosis expression profi les of aggressive breast cancers. In addition, using a new approach of analyzing three-dimensional gene interactions, they have found that the c-MYC gene locus is frequently brought into close proximity with a multitude of genes related to myc or co-amplifi ed in cancer. Forced SATB1 expression in nonaggressive breast cancer cells led to a major change in c-MYC interaction pattern, establishing new connections with genes, some of which are related to cancer (T Kohwi-Shigematsu, personal communication). Th is study provides a concrete example of how the Epigenome Project supports the understanding of the progression from nonaggressive breast cancer to metastatic cancer by establishing genome-wide changes in epigenetic marks, at least in part through global reorganization of higher order chromatin structures by proteins such as SATB1 and others. Th e critical role for chromatin-organizing proteins is refl ected by frequent mutations, such as the recently described mutation of ARID1A in ovarian cancer [47] and other cancers [79] .
In addition, beginning in October 2010, the Epigenome Project began to release data that included more than 300 maps of epigenetic changes in over 56 cell and tissue types, including a number of normal breast cells [80] . For example, one can access data on DNA methylation as well as a number of critical genome-wide histone markers (for example, methylation at lysines K4, K9, K27, and K36). Th ese data should help to defi ne breast cancerspecifi c changes, by allowing researchers to compare the breast cancer data with the normal reference epigenome. Th is, however, brings up one of several hurdles the project must overcome. Th ere are challenges regarding data integration, interpretation, and dissemination -as one would expect given that the technologies used are all relatively new. Th ere is a critical need for the creation of a new generation of tools for interpretation of the numerous epigenetic datasets [81] . Briefl y, in contrast to DNA sequence data, epigenomic data are not digital, diff er in resolution, and are highly variable. Th ese features make comparisons of epigenomes challenging, and require sophisticated informatics tools often not easily accessible for just any general laboratory. Increasing accumulation of data, coupled with improved data and tool integration, and access to computing resources and services, preferably through well-established and proven pipelines, are necessary for the effi cient and successful analysis of the unprecedented increase of epigenetic information.
Epigenetic studies in breast cancer as part of The Cancer Genome Atlas
TCGA began in 2006 as a combined eff ort by the National Cancer Institute and the National Human Genome Research Institute. Th e success of the three-year pilot project led the NIH to commit major resources to TCGA to collect and characterize more than 20 tumor types, including breast cancer. Tumor DNA and RNA will be thoroughly characterized using a number of approaches. Data are currently available for the brain tumor glioblastoma multiforme (GBM) and ovarian cancer, and we can expect more completion of the breast cancer studies by the end of this year.
Currently, epigenomics studies within TCGA use the HumanMethylation27 BeadChip (Illumina, San Diego, CA, USA). Th is assay allows quantitative interrogation of 27,578 CpG loci covering more than 14,000 genes at single-nucleotide resolution. Specifi cally, the panel targets CpG sites located within the proximal promoter regions of 14,475 consensus coding sequences, and in 110 miRNA pro moters. As of April 2011 these data have been available from the TCGA data portal for more than 400 breast cancers [82] , and we can look forward to the report of its fi rst analysis. Of note, a similar TCGAdirected approach in GBM resulted in the identifi cation of a unique glioma CIMP in about 10% of patients, who are usually very young at the time of diagnosis. Th ese patients survive more than 3 years, which is in stark contrast to most GBM patients who survive fewer than 15 months. Interestingly, the study also revealed an association between glioma CIMP with an acquired mutation in the IDH1 gene.
Th e development of these technologies is moving very rapidly, and just when we thought we had a battery of gold standards for genome-wide analysis of DNA methyla tion it becomes clear that additional modifi cations such as hydroxymethyl cytosines, and methylated cytosines outside mCpG islands and outside promoter regions, are likely to play critical roles, including in breast cancer. One may have speculated that the sole analysis of promoter methylation -as done in the TCGA studiesmight miss cancer-specifi c changes in other critical regulatory regions. Th e exciting fi ndings from the GBM study, however, clearly show that promoter methylation includes clinically signifi cant information, and we should look forward to additional data and analyses from the breast cancer TCGA studies.
Conclusions
While an understanding of epigenetic changes in breast cancer has yet to be translated into clinical care, we should expect major steps forward over the next few years. Fundamental discoveries in the understanding of basic epigenetic regulatory mechanisms and dramatic advances in powerful technologies, together with large national and international epigenome projects, will enable identifi cation of breast cancer-specifi c alterations, and thus potential predictive markers and treatment targets. We fi rmly believe we have entered an era of epigenomics that will bring benefi ts for breast cancer patients.
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